GlaxoSmithKline

GSK, Impax Pharmaceuticals terminate collaboration on IPX066

Monday, April 29, 2013 02:25 PM

Impax Pharmaceuticals, the brand products division of Impax Laboratories, and GlaxoSmithKline (GSK) are terminating their collaboration for the development and commercialization of IPX066 outside the U.S. and Taiwan.

More... »

GSK, A*STAR's ICES to develop new medicines for emerging markets

Wednesday, April 10, 2013 09:17 AM

GlaxoSmithKline and A*STAR's Institute of Chemical and Engineering Sciences (ICES) have signed a five-year strategic agreement to develop new evidence based formulations (EBFs) specifically for emerging markets. EBFs are medicines which are reformulated to provide additional patient benefit.\

More... »

BMS appoints Francis Cuss as executive vice president, CSO

Monday, April 8, 2013 03:00 PM

Bristol-Myers Squibb, a global biopharmaceutical company, has appointed Francis Cuss, MB, BChir, FRCP, as executive vice president and chief scientific officer, effective July 1 after Elliott Sigal, M.D., Ph.D., retires.

More... »

EntreMed announces changes to board of directors, CEO appointment

Friday, April 5, 2013 12:05 PM

The board of directors of EntreMed, a clinical-stage pharmaceutical company focused on cancer, has appointed two new individuals as directors. Joining the board are James Huang and Y. Alexander Wu, Ph.D.

More... »

GSK publishes 2012 corporate responsibility report

Wednesday, April 3, 2013 10:18 AM

GlaxoSmithKline has published its Corporate Responsibility Report, in which it reiterates its commitment to operate responsibly, openly and transparently and outlines advances made on this agenda during 2012.

More... »

GSK, Texas A&M to establish influenza vaccine facility in Texas

Friday, March 29, 2013 11:20 AM

The U.S. Department of Health and Human Services (DHHS) has approved GlaxoSmithKline’s (GSK) and The Texas A&M University System’s proposal to establish a $91 million influenza-vaccines manufacturing facility as the anchor of the Center for Innovation in Advanced Development and Manufacturing (CIADM) in Bryan-College Station, Texas.

More... »

PPD appoints Jay Dixon as vice president, global quality and compliance

Tuesday, March 26, 2013 08:00 AM

Pharmaceutical Product Development (PPD), a global CRO, has appointed Jay Dixon as senior vice president, global quality and compliance. Dixon’s expertise will enhance PPD’s ability to deliver industry-leading drug development services and high-quality data across the full spectrum of the research and development life cycle.

More... »

AB-Biotics, GSK sign agreement to promote Neurofarmagen test in Brazil

Friday, March 22, 2013 04:01 PM

GlaxoSmithKline (GSK) and the Spanish biotech company AB-Biotics, have reached an agreement by which GSK will handle the exclusive promotion of Neurofarmagen, the line of pharmacogenetic tests developed by AB-Biotics.

More... »

Chimerix appoints Michael Rogers as chief development officer

Monday, March 18, 2013 09:40 AM

Chimerix, a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, has appointed Michael D. Rogers, Ph.D., as chief development officer.

More... »

Progenitor Labs secures $5.8M to progress regenerative medicine platform

Monday, March 11, 2013 11:36 AM

Progenitor Labs, a regenerative medicine company, has raised $5.8 million in seed financing from the U.K. Fund of SR One, GlaxoSmithKline's independent corporate healthcare venture capital fund.

More... »